Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use

被引:4
|
作者
Shi, Zonggao [1 ,5 ]
Lopez, Jacqueline [2 ]
Kalliney, William [1 ,3 ,5 ]
Sutton, Bobbie [3 ]
Simpson, Joyce [3 ]
Maggert, Kevin [3 ]
Liu, Sheng [4 ,6 ]
Wan, Jun [4 ,6 ]
Stack, M. Sharon [1 ,5 ]
机构
[1] Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN USA
[2] Univ Notre Dame, Genom & Bioinformat Core Facil, Notre Dame, IN USA
[3] South Bend Med Fdn, South Bend, IN USA
[4] Indiana Univ Sch Med, Collaborat Core Canc Bioinformat, Indianapolis, IN USA
[5] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN USA
[6] Indiana Univ Sch Med, Dept Med & Mol Genet, United 0States Amer, Indianapolis, IN USA
来源
PLOS ONE | 2022年 / 17卷 / 04期
关键词
CANCER;
D O I
10.1371/journal.pone.0266914
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
PurposeThe demand for high-throughput genetic profiling of somatic mutations in cancer tissues is growing. We sought to establish a targeted next generation sequencing (NGS) panel test for clinical oncology practice. MethodsCustomized probes were designed to capture exonic regions of 141 genes selected for the panel, which was aimed for the detection of clinically actionable genetic variations in cancer, including KRAS, NRAS, BRAF, ALK, ROS1, KIT and EGFR. The size of entire targeted regions is 0.8 Mb. Library preparation used NEBNext Ultra II FS kit coupled with target enrichment. Paired-end sequencing was run on Illumina NextSeq 500 at a read length of 150 nt. A bioinformatics workflow focusing on single nucleotide variant and short insertions and deletions (SNV/indel) discovery was established using open source, in-house and commercial software tools. Standard reference DNA samples were used in testing the sensitivity and precision and limit of detection in variant calling. ResultsThe general performance of the panel was observed in pilot runs. Average total reads per sample ranged from 30 million to 48 million, 73% ~82% unique reads. All runs had more than 99% average mapping rate. Mean target coverage ranged from 727x to 879x. Depth of coverage at 50x or more reached 87% of targeted region and 60% of targeted region received 500x or more coverage depth. Using OncoSpan HD827 DNA, which bears 144 variants (SNV/indel) from 80 genes that are within the targeted region on the panel, our somatic variant calling pipeline reached 97% sensitivity and 100% precision respectively, with near 48 million reads. High concordance with orthogonal approaches in variant detection was further verified with 7 cancer cell lines and 45 clinical specimens. ConclusionWe developed a NGS panel with a focus on clinically actionable gene mutations and validated the performance in library construction, sequencing and variant calling. High concordance with reference materials and orthogonal mutation detection was observed.
引用
收藏
页数:16
相关论文
共 50 条
  • [11] Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing
    Lee, Paul J.
    Yoo, Naomi S.
    Hagemann, Ian S.
    Pfeifer, John D.
    Cottrell, Catherine E.
    Abel, Haley J.
    Duncavage, Eric J.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2017, 102 (01) : 156 - 161
  • [12] Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making
    Weiss, Glen J.
    Hoff, Brandi R.
    Whitehead, Robert P.
    Sangal, Ashish
    Gingrich, Susan A.
    Penny, Robert J.
    Mallery, David W.
    Morris, Scott M.
    Thompson, Eric J.
    Loesch, David M.
    Khemka, Vivek
    OncoTargets and Therapy, 2015, 8 : 959 - 967
  • [13] CLINICAL APPLICATIONS OF NEXT-GENERATION SEQUENCING
    Gloria Rebollar-Vega, Rosa
    Arriaga-Canon, Cristian
    Alberto de la Rosa-Velazquez, Inti
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2018, 70 (04): : 153 - 157
  • [14] Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer
    Guan, Yan-Fang
    Li, Gai-Rui
    Wang, Rong-Jiao
    Yi, Yu-Ting
    Yang, Ling
    Jiang, Dan
    Zhang, Xiao-Ping
    Peng, Yin
    CHINESE JOURNAL OF CANCER, 2012, 31 (10) : 463 - 470
  • [15] Roadbook for the implementation of next-generation sequencing in clinical practice in oncology and hemato-oncology in Belgium
    Els Van Valckenborgh
    Aline Hébrant
    Aline Antoniou
    Wannes Van Hoof
    Johan Van Bussel
    Patrick Pauwels
    Roberto Salgado
    Waltruda Van Doren
    Anouk Waeytens
    Marc Van den Bulcke
    Archives of Public Health, 76
  • [16] Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel
    Bustos Blanca, de Unamuno
    Estal Rosa, Murria
    Simo Gema, Perez
    Jimenez Inmaculada, de Juan
    Munoz Begona, Escutia
    Serna Mercedes, Rodriguez
    de Miquel Victor, Alegre
    Ros Margarita, Llavador
    Sanchez Rosa, Ballester
    Enguidanos Eduardo, Nagore
    Suela Sarai, Palanca
    Estrada Rafael, Botella
    SCIENTIFIC REPORTS, 2017, 7
  • [17] Roadbook for the implementation of next-generation sequencing in clinical practice in oncology and hemato- oncology in Belgium
    Van Valckenborgh, Els
    Hebrant, Aline
    Antoniou, Aline
    Van Hoof, Wannes
    Van Bussel, Johan
    Pauwels, Patrick
    Salgado, Roberto
    Van Doren, Waltruda
    Waeytens, Anouk
    Van den Bulcke, Marc
    ARCHIVES OF PUBLIC HEALTH, 2018, 76
  • [18] Next-Generation DNA Sequencing: Implications for Oncology Care
    Mahon, Suzanne M.
    ONCOLOGY NURSING FORUM, 2013, 40 (05) : 437 - 439
  • [19] Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis Results from the Onconetwork Immuno-Oncology Consortium
    Fenizia, Francesca
    Alborelli, Ilaria
    Costa, Jose Luis
    Vollbrecht, Claudia
    Bellosillo, Beatriz
    Dinjens, Winand
    Endris, Volker
    Heydt, Carina
    Leonards, Katharina
    Merkelback-Bruse, Sabine
    Pfarr, Nicole
    van Marion, Ronald
    Allen, Christopher
    Chaudhary, Ruchi
    Gottimukkala, Rajesh
    Hyland, Fiona
    Wong-Ho, Elaine
    Jermann, Philip
    Machado, Jose Carlos
    Hummel, Michael
    Stenzinger, Albrecht
    Normanno, Nicola
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2021, 23 (07) : 882 - 893
  • [20] Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel
    Choudhary, Ashish
    Mambo, Elizabeth
    Sanford, Tiffany
    Boedigheimer, Michael
    Twomey, Brian
    Califano, Joseph
    Hadd, Andrew
    Oliner, Kelly S.
    Beaudenon, Sylvie
    Latham, Gary J.
    Adai, Alex T.
    BMC MEDICAL GENOMICS, 2014, 7